Released: March 7, 2022
Department of Defense
Neurofibromatosis Research Program (NFRP)
Anticipated Funding Opportunities for Fiscal Year 2022 (FY22)
The FY22 Defense Appropriations Bill has not been signed into law. Although FY22 funds have not been appropriated for the NFRP, the program is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY22 funding opportunities. This pre-announcement should not be construed as an obligation by the government.
The FY22 Defense Appropriations Act is anticipated to provide funding to the Department of Defense NFRP to support innovative, high-impact NF research. The managing agent for the anticipated funding opportunities is the Congressionally Directed Medical Research Programs at the U.S. Army Medical Research and Development Command.
The FY22 NFRP funding opportunity announcements for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the announcements are released.
Applications submitted to the FY22 NFRP must address one or more of the following Areas of Emphasis:
- Neurofibromatosis (NF) Type 2-related areas (e.g., hearing, balance, ependymoma, meningioma)
- Biomarker discovery, utility, development, and validation
- Non-tumor manifestations not limited to:
- Cognitive Manifestations
- Heterogeneity of NF-related tumors
- Novel disease and treatment response markers using genetics, genomics, epigenetics, systems biology, metabolomics, or similar approaches
- Preclinical efficacy studies
- Target identification, drug discovery
- Nutritional, environmental, and other modifiers of NF
- Health services research
|Award Mechanism||Eligibility||Key Mechanism Elements||Funding|
|Clinical Trial Award||Investigators must be at or above the level of Assistant Professor (or equivalent).||
|Exploration-Hypothesis Development Award||Investigators may be from all academic levels (or equivalent).||
|Investigator-Initiated Research Award||Investigators must be at or above the level of Assistant Professor (or equivalent) and must plan to commit at least a 10% level of effort for each budget period throughout the entirety of the award.||
|New Investigator Award||Early-Stage Investigator (ESI): An independent investigator at or below the level of Assistant Professor (or equivalent) and commit at least 30% during each budget year of their efforts toward the proposed NF research project.
Established Investigator (EI): An independent investigator above the level of Assistant Professor and commit at least 10% during each budget year of their efforts toward the proposed NF research project.
|Early Investigator Research Award||
|Synergistic Idea Award||Investigators must be at or above the level of Assistant Professor (or equivalent).||
A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final funding opportunity announcements that will be available for downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other U.S. Army Medical Research and Development Command extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.
Submission deadlines are not available until the funding opportunity announcements are released. For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the NFRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).
Point of Contact:
CDMRP Public Affairs